Archive | Conferences & Symposiums

Challenges in melanoma clinical research: A snapshot from the Australasian Melanoma Conference 2016

The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.

Read the full story

Posted in Melanoma In The News, Conferences & Symposiums, Information

ASCO Daily News

Immunotherapies and targeted therapies have been approved for the treatment of metastatic melanoma based on clinical studies. However, in clinical practice, it is not easy to contextualize clinical study data. “Important issues arise when treating real world patients with immunotherapies,” said session chair John B. A. G. Haanen, MD, PhD, of the Netherlands Cancer Institute.

Read the full story

Posted in Melanoma In The News, Conferences & Symposiums

One-Third of Patients With Advanced Melanoma Survive at Least 5 Years After Nivolumab Treatment

The news is good from the longest follow-up survival study of patients with advanced melanoma who were treated with the anti–programmed cell death protein 1 (PD-1) agent nivolumab (Opdivo).1 Thirty-four percent of patients who received the drug in a phase I trial (CA909-003) were alive 5 years later. This study, which was presented at the […]

Read the full story

Posted in Melanoma In The News, Clinical Trials, Conferences & Symposiums

ASCO: More Good News for PD-1 Tx of Melanoma

CHICAGO — Patients with advanced melanoma treated with a PD-1 immune checkpoint inhibitor lived more than twice as long as historically treated patients, according to updated results from a large phase I clinical trial.

Read the full story

Posted in Melanoma In The News, Clinical Trials, Conferences & Symposiums

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories